George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
AGM Statement
LiDCO (AIM: LID), the hemodynamic monitoring company, will hold its Annual General Meeting on Monday 1 June 2020 at 10.00 am. As previously communicated, and in line with Government guidelines, only the Chairman of the meeting and one other person will attend the AGM, thus fulfilling the requirement of the Company’s Articles of Association. Ahead of that meeting, the Company provides the following update on trading in the current financial year.
As previously announced on 5 May, LiDCO benefited from a significant uplift in demand for its hemodynamic monitors in Q1 due to COVID-19, with sales of £4.4m for the three months ended 30 April 2020, up 179% on the same period in the prior year and significantly exceeding the £3.5m of sales achieved in H1 last year.
These exceptional conditions appear to have abated somewhat in the earlier part of Q2. There are, however, tentative expectations that elective surgeries will return to usual levels in the coming months and initial signs that the Company’s key markets are beginning to return to more normal conditions. As a result of these factors, we have observed overall sales orders in May that are consistent with the level seen last year. The Board continues to expect that the base of recurring revenues, from its High Usage Programme (HUP) and consumables, which together represented 75% of total sales last year, should continue to generate revenue in the remainder of the year in line with the levels achieved in the latter part of FY20. Although it is early in the year and the pace and extent of a return to normality remains unclear, the exceptionally high sales in Q1 and the persistent recurring revenue being observed mean that the Company is in a healthy position to deliver against management expectations set at the start of the year.
Since the Group’s last announcement, LiDCO has made further progress in its geographical expansion in Latin America, receiving regulatory approval for its latest monitor in Brazil. This follows the recent approval in Colombia and the first sales in-market via its new distributor in Chile.
As at 28 May 2020, the Company had cash of £3.2m (as at 31 January 2020: £1.4m) and the Board remains confident that LiDCO is well placed for when the markets return to normal.
Something brewing? Please share any rumours. Smells of insiders loading ahead of a significant RNS
These two I believe (after a bit of ferreting online) are partof alarge and affluent family from North Dorset and Paul has experience as a hedge fund manager at Rubicon.They also have an interest in another LL P of their own. They are I believe now building a postion here- and why not. Please do your own research.
Aha! I knew it - 12 wretched inches!
Seriously folks, ( this all dates me to 'Goonsville') still wads more sold than bought and the shares are up. Does this mean the seller(s) are finished?
I do not know what to make of this share, but I'm sticking around and if they drop heavily, I may well top up again.
The LiDCO recording and Stockopedia report from our recent webinar can be found in our members area here: https://www.sharesoc.org/seminar/sharesoc-webinar-with-lidco-lid-5-may-2020/
To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: https://www.sharesoc.org/membership/
Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: https://www.sharesoc.org/contact-us/
.... and while many of the actual numbers reflect the fact that this is a microcap (which we all knew), it is growing and Corvid 19 is bringing it much publicity as well as sales and repeat income. I am persuaded that if I were a much larger competitor, and there is one, I would be only too pleased to pounce. They seem to be efficient too, so if they dive back some more, I shall be thinking about topping up.
My other half died of sepsis in 2015. If the hospital had one of LID's monitors, and used it, she might still be here. Sepsis is a growing cause of death. So this has uses other than Corvid 19.
FALLERS, so soon after great news. Weird. If it keeps falling it will undoubtedly change hands for a lot more.
....POP! Does no-one have a shred of confidence here?
...don't vest for some years, so are just a long;term bonus. Not unusual, even for a CFO. Still seems to be more sales than buys.
Extraordinary.
...the takeover. Petty cash for a large-cap. Acc to LSE, more sold than bought - today of all days!
So, Tim Buckley is the Chief Financial Officer [how many have they?]. As such he is the bean counter, not a scientist, not a strategist. So why has he got options over 4 million shares = 1.64% of share capital? These latest 2 million are excerciseable at 0.5p - Yes - half a penny. I have not checked what they actually pay him - what is laughably termed in PLC language as "compensation".
This is an interesting company but it is a small company & has been a serial underperformer. It has now got a lift from the Covid-19 pandemic. Did Mr Buckley have a hand in this? Was he patient zero?
Pigs and troughs are the words that come to mind.
They really are keeping a Lid on this ...
Another RNS out on VOX
Oh I see, thank you Dougal66
200,000. How did he get that many? Hardly any free market - especially now.
What occurring? RNS Not Showing and Nothing Happening?
bought here a few weeks ago bought a few more today going to keep adding when funds available.
off to do some more research
Current market cap... £22m
Fill your boots people..
If it was losses of 6m and an idea we'd probably hit £1. Lol at the markets..
Covid-19 is giving a lift to Lidco's sales but, more importantly is showcasing their hemodynamic monitoring technology internationally.
Lidco's aim has always been for their systems to be a fixture in ALL critical care settings in ALL geographies with advanced healthcare systems.
This is the tipping point for Lidco as a company. Not a "shooting star" but a steady appreciation in value.
LiDCO sales in Q1 of this year (three months ended 30 April 2020) were £4.4m up 179% on the corresponding period last year. As expected, Q1 sales have therefore already significantly exceeded the total sales of £3.5m the Company achieved in H1 last year (6 months to 31 July 2019)
LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring solutions, welcomes the recent educational webinar from the European Society of Intensive Care Medicine ('ESICEM') regarding hemodynamic management in COVID-19 patients. The panel consisted of four international experts who discussed current World Health Organisation COVID-19 treatment guidelines and explored the patient benefits of using advanced hemodynamic monitoring in such treatment.
During the discussions, Senior Consultant Antonio Messina at Humanitas Hospital, Italy discussed the frontline strategies for treating COVID-19 patients and the importance of managing these ventilated patients' physiology with functional hemodynamic tests. During Dr Messina's speech he called out the importance of using a combination of a ventilator and a hemodynamic monitor to perform an end expiratory occlusion test ('EEOT') to assess the patient's fluid status.
This point was reinforced by Professor Jacques Duranteau, Head of Anaesthesia and Critical Care at Bicetre hospital, Paris, who referenced the need to employ a conservative fluid strategy and discussed the use of another ventilator-associated method, the tidal volume challenge ('TVC'), as a means to assess a patient's fluid status to prevent giving COVID-19 patients any excess fluid.
To perform these tests requires a precise measurement of the patient's advanced hemodynamic parameters. The LiDCO monitor is able to meet this need to measure these small changes over a short period of time and is the only monitor on the market to have both the EEOT and TVC as in-built guided clinical protocols.
As previously announced in LiDCO's Full-Year Results release in April 2020, the Company has seen a strong lift in demand for its hemodynamic monitoring systems due to COVID-19. Over 200 monitors have been sold, predominately in the UK, in the first three months of the financial year compared with 219 sold in the whole of previous financial year. LiDCO has been able to supply the monitors to ICU units around the world where patients with the most acute symptoms of COVID-19 are being treated.
LiDCO sales in Q1 of this year (three months ended 30 April 2020) were £4.4m up 179% on the corresponding period last year. As expected, Q1 sales have therefore already significantly exceeded the total sales of £3.5m the Company achieved in H1 last year (6 months to 31 July 2019).
Anyone noticed this site is failing to show the red dot for rns's again, not only that companies that have had rns's today then isn't showing in the rns section of the site. I really didn't think this site could get any worse, it's beyond poor or acceptable. I don't want to have loads of bookmarks open on my tablet just to find a reliable source that tells when an rns is out. What is wrong with lse?
If sales remain steady at this rate for each quarter then that's an annual revenue of £18 million. However, sales are most like going to increase in my opinion.
Webinar today!!!